Study details
Enrolling now
A Phase 2a Trial to Test a New Gel for Diabetic Foot Ulcers
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
NCT IDNCT06852976ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 10 months
Ages
18–75
Locations
1 site in NC
About this study
This trial is testing a new gel (MDI-1228-mesylate gel) compared with the usual treatment alone for people with diabetic foot ulcers. The goal is to see if the new gel helps heal the ulcers faster and reduces the size of the ulcers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Standard of Care Alone
- 2.Take 0.75% MDI-1228_mesylate gel plus Standard of Care
PhasePhase 2
Routeinhaled
Primary goalDrug related treatment emergent adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
inhaled
Endpoints
Primary: Drug related treatment emergent adverse events